These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3572716)

  • 1. In vitro and in vivo evaluation of a sustained release preparation containing phenylpropanolamine hydrochloride.
    Yamakawa I; Shimomura M; Hattori T; Watanabe S; Tsutsumi J; Shinoda A; Miyake Y
    J Pharmacobiodyn; 1986 Dec; 9(12):947-52. PubMed ID: 3572716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained-release dosage form of phenylpropanolamine hydrochloride. Part II: Formulation and in vitro release kinetics from tableted microcapsules.
    Sevgi F; Ozyazici M; Güneri T
    J Microencapsul; 1994; 11(3):335-44. PubMed ID: 8064557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state kinetics of sustained-release phenylpropanolamine.
    Lönnerholm G; Grahnén A; Lindström B
    Int J Clin Pharmacol Ther Toxicol; 1984 Jan; 22(1):39-41. PubMed ID: 6698658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained-release dosage form of phenylpropanolamine hydrochloride. Part I: Microencapsulation and in vitro release kinetics.
    Sevgi F; Ozyazici M; Güneri T
    J Microencapsul; 1994; 11(3):327-34. PubMed ID: 8064556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the release process of phenylpropanolamine hydrochloride from ethylcellulose matrix granules IV.(1)) Evaluation of the controlled release properties for in vivo and in vitro release systems.
    Fukui A; Fujii R; Yonezawa Y; Sunada H
    Chem Pharm Bull (Tokyo); 2007 Nov; 55(11):1569-73. PubMed ID: 17978513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained-release dosage form of phenylpropanolamine hydrochloride (3). Application of factorial design.
    Sevgi F; Ozyazici M; Güneri T
    J Microencapsul; 1994; 11(4):439-44. PubMed ID: 7931943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of phenylpropanolamine in serum and urine by high-performance liquid chromatography.
    Dowse R; Haigh JM; Kanfer I
    J Pharm Sci; 1983 Sep; 72(9):1018-20. PubMed ID: 6631684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hollow fibers as an oral sustained-release delivery system.
    Hussain MA; DiLuccio RC; Shefter E
    Pharm Res; 1989 Jan; 6(1):49-52. PubMed ID: 2717518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained-release phenylpropanolamine hydrochloride bilayer caplets containing the hydroxypropylmethylcellulose 2208 matrix. I. Formulation and dissolution characteristics.
    Ohmori S; Makino T
    Chem Pharm Bull (Tokyo); 2000 May; 48(5):673-7. PubMed ID: 10823705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet.
    Shargel L; Silverman HI; Cohen P; Brisson J; Dennis S
    Biopharm Drug Dispos; 1990 Oct; 11(7):569-83. PubMed ID: 2265237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting.
    Fukui E; Miyamura N; Uemura K; Kobayashi M
    Int J Pharm; 2000 Aug; 204(1-2):7-15. PubMed ID: 11011980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained release phenylpropanolamine hydrochloride from ATO 888 matrix.
    Perez MA; Ghaly ES; Marti A
    P R Health Sci J; 1993 Dec; 12(4):263-7. PubMed ID: 8140204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microencapsulation of phenylpropanolamine to achieve sustained release.
    Prapaitrakul W; Whitworth CW
    J Microencapsul; 1989; 6(2):213-8. PubMed ID: 2723965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative deconvolution. An explicit method for bioavailability comparison not requiring intravenous administration.
    Veng-Pedersen P; Miller R
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):10-4. PubMed ID: 3557723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the release process of phenylpropanolamine hydrochloride from ethylcellulose matrix granules III. Effects of the dissolution condition on the release process.
    Fukui A; Fujii R; Yonezawa Y; Sunada H
    Chem Pharm Bull (Tokyo); 2006 Aug; 54(8):1091-6. PubMed ID: 16880650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of in vitro and in vivo data in the design, development, and quality control of sustained-release decongestant dosage forms.
    Brock MH; Dansereau RJ; Patel VS
    Pharmacotherapy; 1994; 14(4):430-7. PubMed ID: 7524044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations.
    Schran HF; Petryk L; Chang CT; O'Connor R; Gelbert MB
    J Clin Pharmacol; 1996 Oct; 36(10):911-22. PubMed ID: 8930778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of in vivo drug release behavior of controlled-release multiple-unit dosage forms in dogs using a flow-through type dissolution test method.
    Ikegami K; Tagawa K; Kobayashi M; Osawa T
    Int J Pharm; 2003 Jun; 258(1-2):31-43. PubMed ID: 12753751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of three commercial sustained-release papaverine hydrochloride products.
    Timko RJ; Lordi NG
    J Pharm Sci; 1978 Apr; 67(4):496-500. PubMed ID: 25329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets.
    Hu LD; Liu Y; Tang X; Zhang Q
    Eur J Pharm Biopharm; 2006 Oct; 64(2):185-92. PubMed ID: 16797948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.